, Nov. 10, 2011
/PRNewswire/ - Uman Pharma Inc., a Canadian
privately owned generic pharmaceutical company is pleased to announce
the conclusion of a strategic partnership with CFR Pharmaceuticals S.
A. (CFR) of Santiago, Chile
. As part of this transaction CFR acquired a
50.79% shareholding in Uman through a capital investment of C$27.0
. CFR is a publicly traded (CFR) leading Latin American
pharmaceutical company with operations in Latin America
Sylvain Duvernay, Uman Pharma's Chief Executive Officer said: "Among
other corporate purposes, CFR's injection of funds will allow Uman to
increase substantially the number of specialized oncology products to
be developed and manufactured in Candiac, Canada, for commercialization
"By combining our expertise with CFR's sales and marketing team, Uman
has increased its potential to serve the regulated markets for valuable
medications. This association will also open the Emerging Markets for
About Uman Pharma
Uman Pharma is a global pharmaceutical company based in Candiac, on the
south shore of Montreal, Canada. Its strengths lie in the development
and manufacturing of cytotoxic and high potent sterile injectable and
solid dosage products for the oncology market. Uman's portfolio of
products includes proprietary and generic formulations, backed by an
experienced and professional team and GMP manufacturing facilities
(11,700m2) certified for Canada and Europe and in the process to be approved by
the United States FDA.
Please visit www.umanpharma.com for more information.
About CFR Pharmaceuticals
CFR Pharmaceuticals S.A. is a leading Latin American pharmaceutical
company with operations in 15 countries in Latin America (mainly Chile,
Peru, Argentina and Colombia), and other emerging markets. Its business
model is focused on the development, manufacture and commercialization
of off-patent and locally unpatented branded specialty pharmaceutical
products. The company manages its operations along several business
Please visit www.cfr-corp.com for more information.
SOURCE Uman Pharma Inc.